Replies to post #211532 on Biotech Values

[semi_infinite]

The financing seems counter to all the bullish thoughts about TRIL potential. I understand their need for the money but this seems like a CEO/CFO fumble or an acknowledgement of their poor chances of success with trials. Neither one good.